MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan

[ad_1] MaaT Pharma secures important funding in line with one of the goals under the Health Innovation 2030 Plan, the health component of ‘France 2030’, led by the Health Innovation…